Review



polyclonal rabbit antibodies against human cdk9  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc polyclonal rabbit antibodies against human cdk9
    Figure 1. Different <t>CDK9</t> staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.
    Polyclonal Rabbit Antibodies Against Human Cdk9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 197 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+antibodies+against+human+cdk9/CDK9+Rabbit+mAb/pm32901849-42-13-29
    Average 96 stars, based on 197 article reviews
    polyclonal rabbit antibodies against human cdk9 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Targeting CDK9: A novel biomarker in the treatment of endometrial cancer."

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    Journal: Oncology reports

    doi: 10.3892/or.2020.7746

    Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.
    Figure Legend Snippet: Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.

    Techniques Used: Staining

    Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.
    Figure Legend Snippet: Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.

    Techniques Used: Expressing, Western Blot

    Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.
    Figure Legend Snippet: Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.

    Techniques Used: Expressing, Immunohistochemical staining, Staining

    Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.
    Figure Legend Snippet: Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.

    Techniques Used: Concentration Assay, Expressing, Western Blot

    Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.
    Figure Legend Snippet: Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.

    Techniques Used: Knockdown, Transfection, MTT Assay, Inhibition, Control, Expressing, Western Blot

    Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.
    Figure Legend Snippet: Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Techniques Used: Inhibition, Migration

    Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.
    Figure Legend Snippet: Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Techniques Used: Inhibition, Incubation

    Related Articles

    Incubation:

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
    Article Snippet: Antigen was extracted by Dako Target Retrieval Solution (Dako; Agilent Technologies, Inc.), and incubated with 3% H2O2 for 10 min to eliminate endogenous peroxidase activity. .. Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight. .. The slides were fully covered with the anti-rabbit SignalStain® Boost Detection Reagent (Cell Signaling Technology) and placed in a humid chamber for 30 min, and then SignalStain® DAB (Cell Signaling Technology) was added to the slides to reveal the staining intensity.

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer
    Article Snippet: Antigen was extracted by Dako Target Retrieval Solution (Dako; Agilent Technologies, Inc.), and incubated with 3% H 2 O 2 for 10 min to eliminate endogenous peroxidase activity. .. Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight. .. The slides were fully covered with the anti-rabbit SignalStain ® Boost Detection Reagent (Cell Signaling Technology) and placed in a humid chamber for 30 min, and then SignalStain ® DAB (Cell Signaling Technology) was added to the slides to reveal the staining intensity.



    Similar Products

    polyclonal rabbit antibodies against human cdk9  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc polyclonal rabbit antibodies against human cdk9
    Figure 1. Different <t>CDK9</t> staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.
    Polyclonal Rabbit Antibodies Against Human Cdk9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/polyclonal+rabbit+antibodies+against+human+cdk9/CDK9+Rabbit+mAb/pm32901849-42-13-29
    Average 96 stars, based on 1 article reviews
    polyclonal rabbit antibodies against human cdk9 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 1. Different CDK9 staining intensities and H&E staining of endometrial cancer tissues. According to the CDK9 staining in the tumor samples, the staining patterns were divided into 5 groups: i) l<10% positive cells (1+); ii) 10‑25% positive cells (2+); iii) 26‑50% positive cells (3+); iv) 51‑75% positive cells (4+); v) >75% positive cells (5+). (Original magnification, x400). CDK9, cyclin‑dependent kinase 9; H&E, hematoxylin and eosin.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Staining

    Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 3. CDK9 expression in endometrial cancer cell lines. (A) Expression levels of CDK9 in endometrial cancer cell lines (AN3CA, ARK‑2, HEC‑1A, HEC‑1B, lshikawa, RL95‑2 and SPAC1S) as determined by western blotting. (B) Relative expression of CDK9 and α‑tubulin in the endometrial cancer cell lines. CDK9, cyclin‑dependent kinase 9.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Expressing, Western Blot

    Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 2. Higher expression of CDK9 is present in metastatic and recurrent endometrial cancer tissues compared with that found in the patient matched primary tumors and CDK9 is correlated with poor patient prognosis. (A) Distribution of CDK9 immunohistochemical staining scores among primary, metastatic, and recurrent endometrial cancer tissues. (B and C) Correlation between expression of CDK9 in the primary endometrial cancer tissues (Low, CDK9 staining ≤2+; High, CDK9 staining ≥3+) and PFS (B) or OS (C) in endometrial cancer patients by Kaplan‑Meier survival curve analysis. CDK9, cyclin‑dependent kinase 9; PFS, progression‑free survival; OS, overall survival.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Expressing, Immunohistochemical staining, Staining

    Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 5. CDK9 inhibitor reduces endometrial cancer cell proliferation by suppressing transcription elongation and inducing apoptosis in endometrial cancer cells. (A and B) Relative cell viability of AN3CA and SPAC1S cells after exposure to different concentrations of the CDK9 inhibitor LDC067 for 5 days. **P<0.01 compared with the lowest concentration group (1x10‑3 µM). (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after treatment with LDC067 in cells by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator; PARP, poly(ADP‑ribose) polymerase.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Concentration Assay, Expressing, Western Blot

    Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 4. CDK9 knockdown by siRNA transfection suppresses endometrial cancer cell proliferation. (A and B) MTT assay revealed significant dose‑dependent inhibition of cell proliferation after CDK9 siRNA treatment. **P<0.01 compared with the cell only control group. (C and D) Expression levels of CDK9 and related signaling pathway proteins involved in transcription and apoptosis after transfection of CDK9 siRNA and nonspecific siRNA (NC siRNA) in AN3CA and SPAC1S cell lines by western blot analysis. CDK9, cyclin‑dependent kinase 9; Mcl‑1, myeloid cell leukemia‑1; Bax, proapoptotic protein BCL2 associated X, apoptosis regulator.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Knockdown, Transfection, MTT Assay, Inhibition, Control, Expressing, Western Blot

    Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 7. Inhibition of CDK9 reduces endometrial cancer cell migration. (A and B) Representative images of AN3CA and SPAC1S cell migration after CDK9 inhibitor LDC067 treatment for 0, 24, and 48 h. (C and D) Quantification of cell migration distance of AN3CA and SPAC1S cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Inhibition, Migration

    Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Journal: Oncology reports

    Article Title: Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.

    doi: 10.3892/or.2020.7746

    Figure Lengend Snippet: Figure 6. Inhibition of CDK9 suppresses endometrial cancer cell colony formation. (A) Representative images of endometrial cancer cell colony formation after incubation with different concentrations of LDC067 (0, 2.5, 5.0, and 10 µM) for 14 days. (B and C) Quantification of clonogenicity formation of AN3CA (B) and SPAC1S (C) cells after LDC067 treatment. **P<0.01 compared with the Cell only group. CDK9, cyclin‑dependent kinase 9.

    Article Snippet: Thereafter, the slides were sealed with goat serum for 1 h, and then polyclonal rabbit antibodies against human CDK9 (cat. no. 2316; 1:50 dilution in 1% bovine serum albumin; Cell Signaling Technology, Inc.) were added and incubated overnight.

    Techniques: Inhibition, Incubation